



Monitoring for neovascular age-related macular degeneration (AMD)
reactivation at home: the MONARCH study
Elizabeth Ward1 ● Robin A. Wickens1 ● Abby O’Connell1 ● Lucy A. Culliford1 ● Chris A. Rogers1 ● Eleanor A. Gidman1 ●
Tunde Peto 2 ● Paul C. Knox 3 ● Benjamin J. L. Burton4 ● Andrew J. Lotery 5 ● Sobha Sivaprasad6 ●
Michael Donnelly2 ● Charlene Treanor2 ● Ruth E. Hogg2 ● Barnaby C. Reeves 1
Received: 22 October 2019 / Revised: 17 April 2020 / Accepted: 17 April 2020
© The Author(s) 2020. This article is published with open access
Abstract
Aims This study aims to quantify the diagnostic test-accuracy of three visual function self-monitoring tests for detection of
active disease in patients with neovascular age-related macular degeneration (nAMD) when compared with usual care. An
integrated qualitative study will investigate the acceptability of these home-based testing strategies.
Methods All consenting participants are provided with an equipment pack containing an iPod touch with two vision test
applications installed and a paper journal of reading tests. Participants self-monitor their vision at home each week with all
three tests for 12–18 months. Usual care continues over this period. Key eligibility criteria are: age ≥50 years; at least one
eye with AMD with ≥6–≤42 months since first AMD treatment; and vision not worse than Snellen 6/60, LogMAR 1.04 or 33
letters. The primary outcome, and reference standard, is diagnosis of active disease during usual care monitoring in the
Hospital Eye Service. Secondary outcomes include duration of study participation, ability of participants to do the tests,
adherence to weekly testing and acceptability of the tests to participants.
Conclusions Recruitment is in progress at five NHS centres. Challenges in procuring equipment, setting up the devices and
transporting devices containing lithium batteries to participating sites delayed the start of recruitment. The study will
describe the performance of the tests self-administered at home in detecting active disease compared to usual care mon-
itoring. It will also describe the feasibility of the NHS implementing patient-administered electronic tests or similar
applications at home for monitoring health.
Introduction
Wet age-related macular degeneration (neovascular AMD,
nAMD) is the leading cause of vision loss in people aged
≥50 years [1]. Current treatment for nAMD is intravitreal
injections of anti-angiogenic drugs that inhibit vascular
endothelial growth factor (anti-VEGF antibodies). Treat-
ment starts with a loading phase of 3 injections at intervals
of 4–6 weeks; patients then enter a maintenance phase and
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are reassessed at each subsequent hospital monitoring visit
to determine lesion activity. The two main treatment regi-
mens are pro re nata (prn; treatment as required) and treat-
and-extend (prophylactic injections and increasing the time
interval between visits up to 3 months). The frequency of
monitoring depends on the drug prescribed and the treat-
ment regimen. Lesion status can become inactive in a pro-
portion of eyes during the maintenance phase, which are
then treated prn or by treat-and-extend. Relapse is common
with prn treatment and can still occur with a treat-and-
extend regimen.
Monitoring visits use a combination of best-corrected
visual acuity (BCVA), clinical biomicroscopic examination
and optical coherence tomography (OCT) or other retinal
imaging modalities to determine if a lesion is active (wet) or
inactive (dry). Patients may have many months without
requiring treatment and regular monitoring visits place a
significant burden on NHS Hospital Eye Service (HES) out-
patient clinics [2]. Self-monitoring at home (“home-mon-
itoring”) for patients with inactive disease would be more
convenient and less costly for both patients and the NHS. If
self-monitoring were to identify reactivation accurately,
HES clinic appointments could be given only given to
patients likely to require treatment or to newly referred
patients, enabling prompt initiation of treatment.
Home-monitoring with internet-enabled devices is pos-
sible due to development of applications for self-monitoring
visual function in nAMD [3]. Such applications allow
automatic transmission of test results for review without the
need for patients to interpret test results [4, 5]. However,
reactivation of nAMD is difficult to detect because inactive
lesions nevertheless cause some degree of visual disability.
Therefore, any test must detect an increase or change in
visual disability, not just the presence of disability. Tech-
nologies such as visual and memory stimulating grids [6],
preferential hyperacuity perimetry [4, 7] and shape dis-
crimination tests [5, 8–11] have been reported to quantify
distortion more accurately than either the Amsler grid or
visual acuity in clinical settings [3].
The MONARCH study is evaluating three home-
monitoring tests. All have some supporting peer-reviewed
literature and usability data from AMD populations
[5, 6, 8, 9, 12–15]. Two of these tests are electronic
applications that run on an iPod touch and one is a paper
journal of reading puzzles.
Objectives
The objectives of the MONARCH study are:
(a) To estimate the test accuracy of three tests to self-
monitor reactivation of nAMD compared to the
reference standard of detection during usual care
monitoring in HES clinics.
(b) To determine the acceptability of the tests to patients
and carers, explore reasons for non-adherence and the
influence of carers on the acceptability of the tests and
adherence.
(c) To explore whether inequalities (by age, sex, social-
economic status and visual acuity) exist in recruitment
to the study, and are associated with participants’
ability to do the tests and to adhere to weekly testing.
(d) To provide pilot data for using the same home-
monitoring tests to detect conversion to nAMD in
fellow eyes of patients with unilateral disease,
compared to the reference standard of detecting
conversion in usual care monitoring.
Subjects and methods
Study design
The MONARCH study is a multicentre, diagnostic test-
accuracy cohort study. Participants are recruited in sec-
ondary care hospital eye service (HES) clinics. Eligible
patients are asked to use three home-monitoring vision tests
(the index tests) to test their vision weekly at home for a
period of 12–30 months. Participants continue to attend
HES monitoring clinics with retinal imaging carried out as
required to inform usual care management decisions. See
Fig. 1 for the study schema and Supplementary Information
for details of retinal image collection.
There are no safety reporting procedures for this study;
the study is regarded as low risk as it does not require
participants to undergo any additional investigations and
clinical adverse events cannot be attributed to study specific
procedures.
All participating sites are NHS Trusts based in the United
Kingdom (UK). The study has a favourable opinion from
the Northern Ireland Health and Social Care Research
Ethics Committee A (ref 17/NI/0235), is approved by the
Health Research Authority, England and is being conducted
in accordance with established principles of Good Clinical
Practice [16].
Integrated qualitative study
Three sites are also taking part in an integrated qualitative
study (objective B). Person-centred interviews are capturing
difficulties, concerns, fears and perceived benefits about the
index tests. Information about factors that influence suc-
cessful implementation for specific participant subgroups is
also being collected. A qualitative researcher is conducting
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(i) one-to-one home-based interviews and observations of
participants regularly performing the index tests (n= ~75),
(ii) telephone or e-interviews with other subgroups (see
Study Population below), and (iii) interviews with health-
care professionals involved in the recruitment and training
of participants at each site.
Study population
Patients with at least one potential study eye are eligible. A
study eye must have a diagnosis of nAMD meeting the
eligibility criteria. Participants with bilateral nAMD may
have two study eyes if both meet the criteria. A fellow eye
is an eye without nAMD, but which meets all other elig-
ibility criteria. An excluded eye is an eye which is not
eligible to be a study eye or a fellow eye.
Inclusion criteria
A participant aged ≥ 50 years old with at least one
potential study eye is eligible if:
(1) Eye was first treated for active nAMD ≥6 months ago
and ≤42 months ago,
(2) Eye is currently being monitored for nAMD by
the NHS.
Exclusion criteria
A potential study eye is excluded if ANY of the fol-
lowing apply:
(1) Vision is worse than Snellen score 6/60, LogMAR
1.04 or 33 letters;
(2) Vision is limited by a condition other than nAMD;
(3) Surgery in the potential study eye in the previous
6 months;
(4) Refractive error in the potential study eye >−6D;
(5) Retinal or choroidal neovascularisation in the poten-
tial study eye not due to nAMD.
In addition, a participant is excluded if ANY of the
following apply:
(6) Unable to do one or more of the proposed tests during
the training session;
(7) Unable to understand English;
(8) Home or personal circumstances unsuitable for home
testing.
Participants complete the index tests for both study and
fellow eyes. Eye-specific outcomes, such as visual acuity,
are collected at usual care monitoring visits. An excluded
eye can convert to a study eye if time since first treatment
and/or time since surgery reaches 6 months and all other
eligibility criteria are met.
Participants are provided with all equipment required for
the study. Details of all patients approached and reason(s)
Fig. 1 Study schema. The study
schema shows the recruitment
pathway, predicted numbers and
follow-up schedule.
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for non-participation are documented. A minimum dataset
comprising age, sex, visual acuity, index of multiple
deprivation and ethnicity is collected for all patients
approached to monitor inequalities for objective C. Patient
approach is detailed in Supplementary Information.
Study population: integrated qualitative study
Eligibility is not separately assessed for the integrated
qualitative study. Participants and carers who consent to
be contacted are approached directly by the qualitative
research team. Health care professionals willing to be
interviewed are invited for face-to-face, telephone or e-
interview to explore acceptability of study processes and
reasons why patients decline the study. Maximum-
variation and purposive sampling will capture the range
of participant and related-factors that may be potentially
relevant to assessing acceptability (e.g. age, gender and
eye health history) and the role of carers. Patients will be
asked to ‘nominate’ a carer or person who offers personal
support to them. The qualitative sample comprises a
number of subgroups, described in Supplementary
Information.
Stratification
Participants are being recruited into 3 strata according to
time since first treatment for nAMD in a study eye (first-
treated study eye for participants with two study eyes): (a)
6–17 months; (b) 18–29 months; (c) 30–41 months. This
will allow the performance of index tests to be evaluated
across a range of nAMD durations. Approximately equal
recruitment into each stratum is planned.
Home-monitoring (index) tests
The following tests are being evaluated: (a) KeepSight
Journal (KSJ) [6] adapted by the study team for UK use, (b)
MyVisionTrack® (mVT) electronic application [5, 8, 9, 12, 15]
(Genentech Inc.) and (c) MultiBit (MBT) electronic application
[13, 14], developed by Visumetrics, licensed by Novartis
International AG.
The paper-based KSJ was developed by the International
Macular and Retinal Foundation (New Gloucester, Maine,
US). It comprises three tests, viewed one eye at a time: (a)
near visual acuity formatted as a puzzle with varying font
sizes (Fig. 2a), (b) an instruction to assess distortions by
viewing objects with straight lines (Fig. 2b), (c) a modified
Amsler chart to record areas of distortion or scotoma
(Fig. 2b).
Fig. 2 KeepSight journal
puzzles for measuring visual
acuity. Participants complete the
paper KeepSight journal,
containing (a) a reading vision
test, (b) a daily home object test,
and (c) a grid test, weekly.
Fig. 3 MyVisionTrack® (mVT) electronic software application.
Participants select the odd circle out, i.e. irregularly shaped circle;
completing multiple rounds which increase in difficulty.
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mVT is a shape discrimination threshold test displayed on
an iPod Touch. It displays four circles, one of which is
deformed. The participant identifies the odd-one-out (Fig. 3).
MBT is a near acuity threshold test, which displays
numbers made up of receptive field size dots or ‘rarebits’.
These stimuli provide limited information to the visual system
compared to conventional targets. Patients are presented with
pairs of numbers (Fig. 4a) and required to state aloud the
numbers they can see. The numbers are then presented in high
contrast with a recording of the participant’s responses and
the participant marks their own performance (Fig. 4b). We are
validating self-marking in a sample of patients.
Reference standard
The reference standard is the status of the lesion in study eyes
during usual care monitoring in HES clinics, classified as:
definitely active, definitely inactive, or uncertain. Lesion sta-
tus is decided by the ophthalmologist at the clinic visit and not
defined by tests results, although optical coherence tomo-
graphy (OCT) imaging and visual acuity will typically be
available to complement clinical examination. Local site
teams collect data for study and fellow eyes at usual care
monitoring visits when the status of an nAMD lesion and/or
the treatment plan is reviewed, i.e. a “management decision”
is made. See Supplementary Information for the data collec-
tion schedule. Data are also collected on anti-VEGF injections
administered between usual care monitoring visits.
Participant self-reported data
A participant’s willingness to continue in the study, wish for
retraining and self-reported data (e.g. a participant’s own
assessment of their vision) are confirmed by phone or in
person by the local research team before each management
decision in usual care.
Equipment and technical support
Participants are provided with an equipment pack contain-
ing: an eye patch, an iPod with mVT and MBT installed and
activated, a mobile broadband device (MiFi device), a
lens cloth, a stylus pen, a paper KSJ, a pen, instruction
sheets, a weekly checklist and a phone number for technical
support.
The Clinical Trials and Evaluation Unit (CTEU) study
management team receives calls to the technical support
phone line during standard office hours Mon-Fri (except
holidays). Calls received to the support line are documented
and reasons reviewed.
Adherence to home eye testing
Adherence is monitored from test data transmitted to
the CTEU Bristol. Data summaries are reported to the
study management group and study steering committee.
Fig. 4 MultiBit (MBT)
electronic software
application. a Pairs of numbers
are displayed on the screen in
quick succession. Participants
must say the numbers they see
aloud whilst the iPod audio-
records. b At the end of the test,
the numbers which were
presented are displayed clearly
and the audio-recording is
played back to the participant.
Participants have to mark their
performance; if they said the
correct number, they select the
‘Hit’ button below the
corresponding number or if they
said an incorrect number, they
select the ‘Miss’ button.
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Non-adherent participants who have provided consent
for telephone contact are called by CTEU Bristol to ‘trou-




The primary outcome is classification of lesion status in a
study eye.
Secondary outcomes
For Objective C we are measuring outcomes of uptake of
index tests:
(a) Participation in the study, defined as consent (yes/no)
among eligible patients approached to take part.
(b) Ability of participants to do the tests during follow-
up, defined as the proportion of HES monitoring visits for
which some data for an index test are available since the last
HES monitoring visit.
(c) Adherence of participants to weekly testing, defined
as the proportion of weeks for which data for an index test
are available, aggregated across intervals between mon-
itoring visits.
For Objective D, the outcome is onset of active nAMD in
fellow eyes, defined by initiation of treatment.
Masking
All personnel carrying out usual care NHS monitoring
are masked to data from index tests. Site teams are
instructed to report any instance when a participant’s
index test results are seen by a member of the site team,
for example when assisting a patient who is having dif-
ficulties with the equipment/tests, as a protocol devia-
tion. Reasons for deviations are recorded and remedial
actions implemented. Participants may gain an impres-
sion that their vision has changed from home-
monitoring tests.
Features to minimise bias
Risk of bias is considered with respect to bias domains
previously described for diagnostic accuracy studies [17].
Features of the study to protect against bias in each domain
are described in Supplementary Information.
Withdrawal and discharge
Each participant can withdraw from the study at any time.
An investigator may also withdraw a participant at any time.
If a participant is discharged from usual NHS monitoring,
the participant is withdrawn from the study. All withdrawals
are recorded. Data collected up to withdrawal will be used
in analyses, unless consent is withdrawn.
Participants can choose to stop completing one or two of
the index tests and continue in the study. The numbers of
participants withdrawn, lost to follow-up or deceased will
be reported.
Sample size
Objectives A and C
The target sample size is 400 participants with matched
data from home eye testing. The number of visits is the
key parameter and the target is based on assumptions
that: participants will have about 2300 monitoring visits
(average 6 visits/participant, with 5% attrition); nAMD
will be ‘active’ for 30% of monitoring visits; and cor-
relations between tests and reference standard will be 0.6
for both active and inactive lesions [18]. Multiple visits
per participant are not independent and measurement
error will dilute power to discriminate test performance;
therefore, we have assumed an effective sample size of
1200 visits. This number of visits gives 90% power to
detect a difference of 0.06, or 80% power to detect a
difference of 0.05, in the area under the receiver oper-
ating characteristic curves (AUROC) for two tests if the
AUROC is 0.75 [18].
Objective D
Estimates of the rate of conversion to nAMD per year
among fellow eyes vary, ranging from 4 to 16% [19–22].
Assuming the risk in unselected patients is 5–6% per year,
about 50 patients will have nAMD in both eyes at the time
of recruitment. Among the remaining 350 patients, we
expect fellow eyes of about 25–30 patients to convert
to nAMD.
Plan for statistical analysis
For the index texts, alternative threshold criteria for
classification will be explored to maximise test
performance.
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Objective A
The study will be analysed and reported in line with
reporting guidelines for studies of diagnostic accuracy [23]
and will follow a statistical analysis plan that will be written
in advance of the analyses being carried out. We are unable
to prespecify the analyses in detail because of the early
stage of evaluation of the index tests.
Sensitivity, specificity, positive and negative predictive
values of each test will be reported with 95% confidence
intervals. The overall performance of the tests will be
quantified by the AUROC. AUROCs for the tests will be
compared to determine if one or more tests is superior to
one or more of the others. Analyses will take account of the
structure within the data, i.e. the nesting of visits (and eyes)
within patients.
Other analyses may be explored to investigate whether
the performance of home-monitoring overall can be
improved by, for example, combining information: (a) from
multiple index tests; (b) from adjacent home-monitoring
periods preceding a monitoring visit (to see if there is evi-
dence that index tests provide ‘advance warning’ of nAMD
becoming active); (c) for the study eye and an unaffected
fellow eye (to see if differences in scores between affected
and unaffected eyes contribute to test accuracy). See Sup-
plementary Information for further details.
Objective B
Interviews will be audio-recorded and transcribed for analysis
and reporting. The research team will review results itera-
tively and data will be managed and analysed using NVivo
software and content and thematic analytical strategies
[24, 25]. The focus of the analysis will be on, for example, the
acceptability of the tests, the factors that facilitate or impede
such acceptability, ease/difficulty of using each test and the
perceived benefits as well as the role of carers and family
members [26]. The transcripts of interviews will be analysed
to produce an integrated and synthesised account and inter-
pretation of the acceptance of the new tests. The qualitative
researchers and wider research team will meet to discuss
iteratively and early on the results of the analysis including
the generation of codes and categories from the content of the
transcripts [27]. Overall, the rigour, transparency and sensi-
tivity of the methodology [28] will be enhanced by following
the consolidated criteria for reporting qualitative research
(COREQ) such as respondent validation, reflexivity and dis-
cussion of analytical codes and categories [29].
Objective C
Regression models will be fitted to explore the influences of
age, sex, social-economic status and visual acuity at
recruitment on the outcomes of: consent to take part (among
all patients approached); ability of a participant to complete
a test, analysed separately for each index test (among all
participants); and adherence to the study protocol (among
all participants). The influence of these factors will be
reported as odds ratios with 95% confidence intervals.
Analyses will take account of nesting of visits within
participants.
Objective D
All analyses for objective D will be descriptive only. We
will explore how test accuracy for detecting conversion
changes as a function of index test scores and report the test
accuracy statistics for each test for detecting conversion,
with 95% confidence intervals.
Frequency of analyses
For study objectives A, C and D, the primary analysis will
take place when follow-up is complete for all recruited
participants. No formal interim analysis is planned.
Data for objective B will be analysed iteratively during
the study and there are no planned subgroup analyses. Study
findings will be reported descriptively by strata.
Study management and monitoring
See supplementary information for details.
Protocol amendments
Version 3.0, in use since 30/05/2019, superseded version
2.0 which was used when recruitment started. The changes
included lowering the minimum visual acuity threshold
from Snellen 6/24, LogMAR 0.64 or 53 letters to Snellen 6/
60, LogMAR 1.04 or 33 letters, the addition of interviews
with healthcare professionals to address objective B and
postal newsletters for participants.
Discussion
Recruitment started on 31/07/2018. Recruitment and index
test data collection has been challenging, primarily due to
technical difficulties.
(a) During set-up, sites queried insurance, warranties and
guarantees for liability of high-value equipment.
(b) Study staff were inexperienced in setting-up multiple
device management software to maintain a large
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number of iPod devices.
(c) Distributing study equipment has been affected by
restrictions on transporting devices containing lithium
ion batteries by air.
(d) Mobile phone signal coverage at participant’s homes and
at NHS sites is limited. The mVT and MBT applications
require internet connectivity by the MiFi device.
Difficulties with internet connectivity is a common
reason for home eye test data not being transmitted.
(e) Faults and updates to software applications and Apple
operating systems have caused interruptions to the
availability of the index tests at participants’ homes.
Monitoring adherence to weekly home-monitoring is an
important consideration. Following up participants who are
not testing is time-consuming.
The results of this study will fill a gap in knowledge
regarding the test-accuracy of home-monitoring for diag-
nosis of nAMD reactivation and the practicality of using
home-monitoring with electronic devices in this patient
group. After publication of the study results, the anon-
ymised data will be made available upon reasonable request
to the Sponsor institution, The Queen’s University of Bel-
fast. The protocol includes a statement on data sharing [30].
Summary
What was known before
● Wet age-related macular degeneration (nAMD) is the
leading cause of vision loss in people aged ≥50 years.
Whilst nAMD lesions can become inactive following
treatment, relapse is common.
● Patients may have many months without requiring
treatment and regular monitoring visits place a sig-
nificant burden on NHS Hospital Eye Service (HES)
out-patient clinics.
● Self-monitoring at home for patients with inactive
disease would be more convenient and less costly for
both patients and the NHS. HES clinic appointments
could be given only to patients likely to require
treatment or to newly referred patients.
What this study adds
● The MONARCH study is a multi-centre diagnostic test-
accuracy cohort study evaluating three home-monitoring
tests: two electronic tests using an iPod and one paper
journal.
● The objectives of the MONARCH study are to estimate
the test accuracy of the tests to self-monitor reactivation
of nAMD, to determine the acceptability of the tests to
patients and carers, to explore whether inequalities exist
in recruitment, and to provide pilot data for using the
same home-monitoring tests to detect conversion to
nAMD in fellow eyes.
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